CBD Shows Promise Against Alzheimer's in Lab and Computer Studies
A comprehensive review found CBD targets multiple Alzheimer's disease pathways in preclinical research, with computer modeling identifying potential gene targets.
Quick Facts
What This Study Found
CBD has demonstrated effects on amyloid plaques, tau protein, neuroinflammation, oxidative stress, and cholinergic pathways in preclinical Alzheimer's models. In silico analysis mapped the gene network and biological pathways involved in CBD's mechanism of action.
Key Numbers
Review synthesizes preclinical evidence; in silico analysis mapped differential gene expression networks. Specific gene targets identified in full text.
How They Did This
Comprehensive literature review combined with in silico (computer-based) analysis of gene expression data to map CBD's mechanism of action in Alzheimer's disease pathways.
Why This Research Matters
Alzheimer's treatments remain limited and often ineffective. Identifying how CBD interacts with multiple disease pathways could open new avenues for complementary treatment research.
The Bigger Picture
The multitarget nature of CBD is both promising and challenging. Alzheimer's is driven by multiple interacting pathologies, and a compound that addresses several simultaneously could theoretically be more effective than single-target drugs.
What This Study Doesn't Tell Us
Evidence is almost entirely preclinical (animal and cell studies) and computational. No human clinical trial data for CBD in Alzheimer's was included. In silico predictions require experimental validation.
Questions This Raises
- ?Will CBD's preclinical promise translate to human clinical trials for Alzheimer's?
- ?What doses and formulations would be needed?
- ?How does CBD interact with existing Alzheimer's medications?
Trust & Context
- Key Stat:
- CBD affects amyloid, tau, inflammation, and cholinergic pathways in preclinical models
- Evidence Grade:
- Comprehensive review with novel computational analysis, but limited to preclinical evidence without human trial data.
- Study Age:
- 2025 review synthesizing the latest preclinical and computational evidence.
- Original Title:
- Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions.
- Published In:
- The European journal of neuroscience, 62(4), e70229 (2025)
- Authors:
- Mello-Hortega, João V, de Oliveira, Carolina S, de Araujo, Vitoria S, Furtado-Alle, Lupe, Tureck, Luciane V, Souza, Ricardo L R
- Database ID:
- RTHC-07116
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can CBD treat Alzheimer's disease?
Preclinical research shows CBD interacts with multiple Alzheimer's disease pathways, but all evidence so far comes from lab and animal studies. Human clinical trials have not yet confirmed these effects.
How might CBD work against Alzheimer's?
Research suggests CBD may reduce amyloid plaque formation, limit tau protein problems, reduce brain inflammation, combat oxidative stress, and support the cholinergic system, which is critical for memory.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-07116APA
Mello-Hortega, João V; de Oliveira, Carolina S; de Araujo, Vitoria S; Furtado-Alle, Lupe; Tureck, Luciane V; Souza, Ricardo L R. (2025). Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions.. The European journal of neuroscience, 62(4), e70229. https://doi.org/10.1111/ejn.70229
MLA
Mello-Hortega, João V, et al. "Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions.." The European journal of neuroscience, 2025. https://doi.org/10.1111/ejn.70229
RethinkTHC
RethinkTHC Research Database. "Cannabidiol and Alzheimer Disease: A Comprehensive Review an..." RTHC-07116. Retrieved from https://rethinkthc.com/research/mello-hortega-2025-cannabidiol-and-alzheimer-disease
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.